Jun Ding
Zhejiang University
8 Papers
18 Citations
Jun Ding is an academic researcher from Zhejiang University. The author has contributed to research in topics: Medicine & Chemistry. The author has an hindex of 4, co-authored 5 publications.
Chat about Author
Papers
Identification of potential miRNA–mRNA regulatory network contributing to pathogenesis of HBV-related HCC
Weiyang Lou,Jingxing Liu,Bisha Ding,Danni Chen,Liang Xu,Jun Ding,Donghai Jiang,Lin Zhou,Shusen Zheng,Weimin Fan +9 more
TL;DR: In the study, potential miRNA–mRNA regulatory pathways were identified, exploring the underlying pathogenesis and effective therapy strategy of HBV-related HCC and suggested that these predicted targets were linked to hepatitis B, pathways in cancer, microRNAs in cancer and viral carcinogenesis.
Decreased propionyl-CoA metabolism facilitates metabolic reprogramming and promotes hepatocellular carcinoma.
Jiaqi Sun,Jun Ding,Qingsong Shen,Xiyang Wang,Min Wang,Yongping Huang,Xuechun Zhang,Hua Zhu,Feng zhang,Dongde Wu,Min-Wen Peng,Zhonglin Zhang,Yufeng Yuan,Wenhua Li,Zhi-Gang She,Xiao‑Jing Zhang,Hongliang Li,Peng Zhang,Zan Huang +18 more
TL;DR: In this article , the role of propionyl-CoA metabolism in hepatocellular carcinoma (HCC) was dissected and the potential targets for development of novel strategies against HCC were uncovered.
26
FAM83D associates with high tumor recurrence after liver transplantation involving expansion of CD44+ carcinoma stem cells.
Bin-Yi Lin,Tianchi Chen,Qijun Zhang,Xiaoxiao Lu,Zhiyun Zheng,Jun Ding,Jinfeng Liu,Zhe Yang,Lei Geng,Liming Wu,Lin Zhou,Shusen Zheng +11 more
TL;DR: FAM83D provides a novel therapeutic approach against HCC recurrence after LT by promoting CD44 expression and CD44+ CSCs malignancy and activating the MAPK, TGF-β and Hippo signaling pathways.
SMYD2 Promotes Hepatocellular Carcinoma Progression by Reprogramming Glutamine Metabolism via c-Myc/GLS1 Axis
Kangdi Xu,Jun Ding,Dazhi Li,Jia Luo,Wenchao Wang,Mingge Shang,Bingyi Lin,Lin Zhou,Shusen Zheng +8 more
TL;DR: In this paper , the authors investigated the role of methyltransferase SET and myND domain-containing protein 2 (SMYD2) in hepatocellular carcinoma (HCC) and showed that the depletion of SMYD2 inhibits HCC cell growth.
Development and validation of novel prognostic models based on RNA-binding proteins in breast cancer
TL;DR: The results indicate that the OS and RFS models are good prognostic models with reliable predictive abilities and can be used as reliable BRCA prognostic biomarkers.